Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
PR Newswire —
Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients Rezpegaldesleukin proof-of-concept data in alopecia areata patients presented as a late-breaking research oral presentation SAN...